scholarly journals Effect of panretinal photocoagulation on macular morphology and thickness in eyes with proliferative diabetic retinopathy without clinically significant macular edema

2012 ◽  
pp. 2013 ◽  
Author(s):  
Sunil Ganekal ◽  
Manoj Soman ◽  
Unni Krishnan Nair ◽  
KGR Nair
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Proliferative Diabetic Retinopathy ◽  
Panretinal Photocoagulation ◽  
Clinically Significant Macular Edema ◽  
Clinically Significant

EFFECT OF INTRAVITREALANTI VEGF COMBINED WITH MACULAR LASER IN A CASE OF PROLIFERATIVE DIABETIC RETINOPATHY WITH CLINICALLY SIGNIFICANT MACULAR EDEMA

2021 ◽  
pp. 3-3
Author(s):  
Prachi Mathur ◽  
Rakesh Porwal
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Laser Therapy ◽  
Diabetic Macular Edema ◽  
Proliferative Diabetic Retinopathy ◽  
Combined Effect ◽  
Panretinal Photocoagulation ◽  
Working Adults ◽  
Clinically Significant Macular Edema ◽  
Clinically Significant

Diabetic retinopathy specically Diabetic macularedema is the leading cause of new cases of blindness in working adults. We here discuss a case of a 50 year old male diabetic with clinically signicant macular edema who received a dose of intravitreal antiVEGF followed by panretinal photocoagulation 3 weeks later and macular laser at the end of 3rd month. On various followups there was a serial decrease in macular thickness. This case emphasizes on the fact that combined effect of AntiVEGF therapy with laser therapy has a benecial role in Proliferative Diabetic retinopathy with Diabetic Macular Edema.

scholarly journals Macular thickness in diabetic retinopathy without clinically significant macular edema

2018 ◽  
Vol 16 (2) ◽  
pp. 64-78
Author(s):  
Krishna Rao ◽  
Ravi Chandra ◽  
Lavanya Rao ◽  
Shailaja S ◽  
Manali Hazarika
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Proliferative Diabetic Retinopathy ◽  
Cross Sectional Study ◽  
Macular Thickness ◽  
Cross Sectional ◽  
Significant Difference ◽  
Central Subfield Thickness ◽  
Clinically Significant Macular Edema ◽  
Clinically Significant

Aim: To measure macular thickness by optical coherence tomography (OCT) in various grades of diabetic retinopathy with no clinically significant macular edema (CSME) and its comparison with non-diabetics. Design: Prospective cross–sectional study. Methods: Macular thickness was measured by OCT in 72 healthy volunteers (107 control eyes), 45 patients with mild and moderate non-proliferative diabetic retinopathy (NPDR) (78 eyes) and 37 patients with severe NPDR and proliferative diabetic retinopathy (PDR) (66 eyes). Patients with diabetic macular edema (DME) as assessed by stereoscopic evaluation or photographs were excluded. One-way ANOVA test to compare the mean thickness and Tukey's test for multiple comparison between groups were used. Results: Central subfield thickness (CST) was 238.57 ± 25.077 µm, 251.22 ± 24.649 µm, and 270.45 ± 28.956 µm in the three groups respectively. As the severity of retinopathy increased, the macular thickness significantly increased (p = < 0.001) in all the nine zones on OCT. There was a significant increase in CST noted in all the grades of retinopathy when compared with non-diabetics (p = 0.004, p = < 0.0001). No significant difference in macular thickness was noted between genders, irrespective of their groups (p = 0.72), or between the three groups in all the nine zones (p = 0.609). Conclusion: There is a significant increase in CST in all grades of retinopathy, as well as with increasing severity of retinopathy when compared to non-diabetics. This warrants the need to obtain OCT measurements even in patients with moderate NPDR without CSME to rule out subclinical DME.

INTRAVITREAL TRIAMCINOLONE AS AN ADJUNCT TO STANDARD LASER THERAPY IN COEXISTING HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY AND CLINICALLY SIGNIFICANT MACULAR EDEMA

Retina ◽  
2010 ◽  
Vol 30 (2) ◽  
pp. 254-259 ◽  
Author(s):  
AHMAD MIRSHAHI ◽  
HAMIDEH SHENAZANDI ◽  
ALIREZA LASHAY ◽  
HUSHANG FAGHIHI ◽  
ASOO ALIMAHMOUDI ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
High Risk ◽  
Macular Edema ◽  
Laser Therapy ◽  
Proliferative Diabetic Retinopathy ◽  
Intravitreal Triamcinolone ◽  
Clinically Significant Macular Edema ◽  
Clinically Significant ◽  
Standard Laser

scholarly journals Diabetic retinopathy with or without clinically significant macular edema: The influencing factors

2016 ◽  
Vol 7 (2) ◽  
pp. 142-147
Author(s):  
Barsha Suwal ◽  
Jeevan Kumar Shrestha ◽  
Sagun Narayan Joshi ◽  
Ananda Kumar Sharma
Keyword(s):  
Diabetic Retinopathy ◽  
Glycemic Control ◽  
Macular Edema ◽  
Total Cholesterol ◽  
Cholesterol Level ◽  
Total Cholesterol Level ◽  
Density Lipoprotein ◽  
Diabetic Patients ◽  
Clinically Significant Macular Edema ◽  
Clinically Significant

Introduction: Diabetic retinopathy is the commonest micro vascular complication in patients with diabetes and remains a leading cause of blindness in people of working age group. Objective: to determine the prevalence of clinically significant macular edema (CSME) and the influence of systemic risk factors Materials and methods: It is a hospital based comparative study conducted in 220 eyes of 110 diabetic patients. DR was graded according to International Clinical Diabetic Retinopathy Severity Scale and CSME was defined according to Early Treatment Diabetic Retinopathy Study (ETDRS) system. The patients were grouped as 1) CSME group (DR and CSME in one or both eyes) and 2) Non- CSME group(CSME in none of the eyes but with any grade of DR).Level of glycosylated hemoglobin (HbA1C), serum total cholesterol, triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein (HDL) and urine for albumin were studied in both groups. Results: CSME was present in 36% of 110 patients. Poor glycemic control and high total cholesterol level showed positive association with CSME (p<0.05). LDL and TG levels were higher and HDL lower in CSME group. However, no statistical significance was found. Conclusion: The CSME is significantly associated with poorer glycemic control and elevated total cholesterol level.

scholarly journals Management of Diabetic Retinopathy

2021 ◽  
pp. 95-103
Author(s):  
Marieta Dumitrache ◽  
Rodica Lascu
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Effective Treatment ◽  
Prophylactic Treatment ◽  
Vision Loss ◽  
Vitreous Hemorrhage ◽  
Tractional Retinal Detachment ◽  
Clinically Significant Macular Edema ◽  
Clinically Significant ◽  
Photocoagulation Laser

Management in D.R. through prophylactic treatment (maintaining a glycemic level as close as possible to normal, control hypertension <150/85 mmHg, hyperlipidemia) and curative treatment of D.R. does not cure the disease, but may slow the evolution of D.M. and D.R. AntiVEGF agents are indicated as adjuvant therapy in pan-photocoagulation laser and / or vitrectomy in patients with DR to block angiogenesis by inhibiting VEGF. All antiVEGF agents are an effective treatment for the clinically significant macular edema. Photocoagulation laser is a treatment of choice in preproliferative and proliferative DR and an effective treatment of diabetic macular edema. The indications for laser treatment in diabetic retinopathy are related to the incidence, evolution of neovessels, duration of diabetes, HbA1c level, presence of macular edema, stage of DR. The laser for macular lesions reduces the risk of vision loss in the eyes with incipient and moderate non-proliferative DR and macular edema concomitant; the laser should be applied to all patients with clinically significant macular edema. Vitrectomy in proliferative DR is indicated in vitreous hemorrhage, tractional retinal detachment in order to remove the vitreous hermorrhage and excision of tractional preretinal membranes.

SPONTANEOUS RESOLUTION OF MACULAR EDEMA AFTER PANRETINAL PHOTOCOAGULATION IN FLORID PROLIFERATIVE DIABETIC RETINOPATHY

Retina ◽  
2009 ◽  
Vol 29 (9) ◽  
pp. 1282-1288 ◽  
Author(s):  
DAVID GAUCHER ◽  
PINA FORTUNATO ◽  
AMÉLIE LECLEIRE-COLLET ◽  
TRISTAN BOURCIER ◽  
CLAUDE SPEEG-SCHATZ ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Proliferative Diabetic Retinopathy ◽  
Spontaneous Resolution ◽  
Panretinal Photocoagulation

scholarly journals Treatment of diabetic macular edema and proliferative diabetic retinopathy with anti-vascular endothelial growth factor agents under the reimbursement policy of the Taiwan National Health Insurance Bureau: Aflibercept or ranibizumab?

2021 ◽  
Author(s):  
Ming-Chieh Hsieh ◽  
Chieh-Yin Cheng ◽  
Kun-Hsien Li ◽  
Chih-Chun Chuang ◽  
Jian-Sheng Wu ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Proliferative Diabetic Retinopathy ◽  
Case Series ◽  
Incidence Rates ◽  
Panretinal Photocoagulation ◽  
Reimbursement Policy ◽  
Micropulse Laser ◽  
The Mean

Abstract The purpose of this retrospective interventional case series is to compare the functional and anatomical outcomes in eyes with diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) treated intravitreally with aflibercept or ranibizumab under the Taiwan National Insurance Bureau reimbursement policy. 84 eyes were collected and all eyes were imaged with spectral-domain optical coherence tomography (SD-OCT), color fundus photographs (CFPs), and fluorescein angiography (FA). At 24 months after therapy initiation, the logMAR BCVA improved from 0.58 ± 0.33 to 0.47 ± 0.38 (p < 0.01), the CRT decreased from 423.92 ± 135.84 to 316.36 ± 90.02 (p < 0.01), and the number of microaneurysms decreased from 142.14 ± 57.23 to 75.32 ± 43.86 (p < 0.01). The mean injection count was 11.59 ± 6.54. There was no intergroup difference in logMAR BCVA (p = 0.96), CRT (p = 0.69), or injection count (p = 0.81). However, the mean number of microaneurysms was marginally reduced (p = 0.06) in eyes treated with aflibercept at the end of the follow-up, and the incidence rates of supplementary panretinal photocoagulation (PRP) (p = 0.04) and subthreshold micropulse laser (SMPL) therapy sessions (p = 0.01) were also reduced. Multivariate analysis revealed that only initial logMAR BCVA influenced the final VA improvements (odds ratio (OR) 0.49, 95% confidence interval (CI) 0.21 ~ 0.93, p < 0.01); in contrast, age (OR -0.38, 95% CI -6.97~-1.85, p < 0.01) and initial CRT (OR 0.56, 95% CI 0.34 ~ 0.84, p < 0.01) both influenced the final CRT reduction at 24 months. To sum up, both aflibercept and ranibizumab are effective in managing DME with PDR in terms of VA, CRT and MA count. Eyes receiving aflibercept required less supplementary PRP and SMPL treatment than those receiving ranibizumab. The initial VA influenced the final VA improvements at 24 months, while age and initial CRT were prognostic predictors of 24-month CRT reduction.

Sign in / Sign up

Export Citation Format

Share Document